A Phase 1 interventional study of Olaparib and Tamoxifen in Solid Tumours, sponsored by AstraZeneca. Completed at 14 sites in 5 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-10-02.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label 2-part Phase I study in patients with advanced solid tumours. Part A of the study (mandatory) will assess the effect of olaparib on the pharmacokinetics (PK) of anastrozole, letrozole and tamoxifen and vice versa; Part B will allow patients (if eligible) continued access to olaparib after the PK phase and will provide additional safety data.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 79 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Histological or cytological confirmation of any malignant solid tumour in an advanced or setting who meet one of the criteria below:
Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:
Evidence of non-childbearing status for women of , or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on Day 1 of Part A.
Postmenopausal is defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Olaparib-alone Steady state PK, Tamoxifen-alone steady state PK, Combined olaparib and Tamoxifen steady state PK.
Drug: Olaparib · Drug: Tamoxifen · Procedure: Pharmacokinetic sampling
Olaparib-alone Steady state PK, Anastrozole-alone steady state PK, Combined olaparib and Anastrozole steady state PK.
Drug: Olaparib · Drug: Anastrozole · Procedure: Pharmacokinetic sampling
Olaparib-alone Steady state PK, Letrozole-alone steady state PK, Combined olaparib and Letrozole steady state PK.
Drug: Olaparib · Drug: Letrozole · Procedure: Pharmacokinetic sampling
2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
1mg Anastrozole once daily Day 10 - Day 24
2.5mg Letrozole once daily Day 10 - Day 43
Blood sampling over 12-24 hour period for pharmacokinetic analysis
Effect of Olaparib on Exposure to Tamoxifen - Cmax ss
Tamoxifen, N-desmethyl tamoxifen (N-DMT) and endoxifen Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios
Time frame: Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31
Effect of Tamoxifen on Exposure to Olaparib - Cmax ss
Olaparib Cmax ss in the presence and absence of co-administered tamoxifen, and associated Cmax ss treatment ratios
Time frame: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31
Effect of Olaparib on Exposure to Anastrozole - Cmax ss
Anastrozole maximum plasma concentration at steady state (Cmax ss) in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios
Time frame: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24
Effect of Anastrozole on Exposure to Olaparib - Cmax ss
Olaparib Cmax ss in the presence and absence of co-administered anastrozole, and associated Cmax ss treatment ratios
Time frame: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24
Effect of Olaparib on Exposure to Letrozole - Cmax ss
Letrozole Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios
Time frame: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43
Effect of Letrozole on Exposure to Olaparib - Cmax ss
Olaparib Cmax ss in the presence and absence of co-administered letrozole, and associated Cmax ss treatment ratios
Time frame: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43
Effect of Olaparib on Exposure to Tamoxifen - AUC0-τ
Tamoxifen, N-DMT and endoxifen AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios
Time frame: Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31
Effect of Tamoxifen on Exposure to Olaparib - AUC0-τ
Olaparib AUC0-τ, in the presence and absence of co-administered tamoxifen, and associated AUC0-τ treatment ratios
Time frame: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31
Effect of Olaparib on Exposure to Anastrozole - AUC0-τ
Anastrozole Area under plasma concentration-time curve over the dosing interval at steady state (AUC0-τ), in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios
Time frame: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24
Effect of Anastrozole on Exposure to Olaparib - AUC0-τ
Olaparib AUC0-τ, in the presence and absence of co-administered anastrozole, and associated AUC0-τ treatment ratios
Time frame: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24
Effect of Olaparib on Exposure to Letrozole - AUC0-τ
Letrozole AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios
Time frame: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43
Effect of Letrozole on Exposure to Olaparib - AUC0-τ
Olaparib AUC0-τ, in the presence and absence of co-administered letrozole, and associated AUC0-τ treatment ratios
Time frame: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43
First patient enrolled: 01 Sep 2014; last completed Part A: 28 Apr 2015. Last patient completed Part B: 27 Apr 2016. Part A assessed olaparib's effect on the pharmacokinetic (PK) parameters of anastrozole, letrozole and tamoxifen and vice versa; in Part B eligible patients received olaparib providing further safety data. Target accrual was met.
| Milestone | Cohort 1 - Tamoxifen | Cohort 2 - Anastrozole | Cohort 3 - Letrozole | Olaparib (Part B) |
|---|---|---|---|---|
| Started | 30 | 23 | 26 | 0 |
| Completing treatment period 1 | 29 | 22 | 23 | 0 |
| Completing treatment period 2 | 29 | 21 | 23 | 0 |
| Completing treatment period 3 | 28 | 21 | 23 | 0 |
| Completed | 28 | 21 | 23 | 0 |
| Not completed | 2 | 2 | 3 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 |
| Withdrew: Condition under investigation worsened | 2 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Milestone | Cohort 1 - Tamoxifen | Cohort 2 - Anastrozole | Cohort 3 - Letrozole | Olaparib (Part B) |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 69 |
| Completed | 0 | 0 | 0 | 6 |
| Not completed | 0 | 0 | 0 | 63 |
| Withdrew: Patient decision | 0 | 0 | 0 | 3 |
| Withdrew: Disease progression | 0 | 0 | 0 | 4 |
| Withdrew: Complete response | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event + disease progression | 0 | 0 | 0 | 1 |
| Withdrew: Lack of therapeutic response | 0 | 0 | 0 | 12 |
| Withdrew: Condition under investigation worsened | 0 | 0 | 0 | 39 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
Tamoxifen, N-desmethyl tamoxifen (N-DMT) and endoxifen Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios
| mcg/mL | Cohort 1 - Tamoxifen Alone (Treatment Period 2) | Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) |
|---|---|---|
| PK analysis of tamoxifen | 130.3 ± 27.3 | 154.2 ± 34.9 |
| PK analysis of N-DMT | 162.9 ± 28.0 | 149.1 ± 44.8 |
| PK analysis of endoxifen | 5.923 ± 65.7 | 5.727 ± 61.2 |
Olaparib Cmax ss in the presence and absence of co-administered tamoxifen, and associated Cmax ss treatment ratios
| mcg/mL | Cohort 1 - Olaparib (Treatment Period 1) | Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) |
|---|---|---|
| Effect of Tamoxifen on Exposure to Olaparib - Cmax ss | 9.456 ± 41.5 | 7.216 ± 43.6 |
Anastrozole maximum plasma concentration at steady state (Cmax ss) in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios
| micrograms per millilitre (mcg/mL) | Cohort 2 - Anastrozole Alone (Treatment Period 2) | Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) |
|---|---|---|
| Effect of Olaparib on Exposure to Anastrozole - Cmax ss | 40.98 ± 36.2 | 35.83 ± 31.9 |
Olaparib Cmax ss in the presence and absence of co-administered anastrozole, and associated Cmax ss treatment ratios
| mcg/mL | Cohort 2 - Olaparib (Treatment Period 1) | Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) |
|---|---|---|
| Effect of Anastrozole on Exposure to Olaparib - Cmax ss | 9.490 ± 34.3 | 8.256 ± 39.9 |
Letrozole Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios
| mcg/mL | Cohort 3 - Letrozole Alone (Treatment Period 2) | Cohort 3 - Olaparib + Letrozole (Treatment Period 3) |
|---|---|---|
| Effect of Olaparib on Exposure to Letrozole - Cmax ss | 118.9 ± 32.6 | 111.8 ± 30.4 |
Olaparib Cmax ss in the presence and absence of co-administered letrozole, and associated Cmax ss treatment ratios
| mcg/mL | Cohort 3 - Olaparib (Treatment Period 1) | Cohort 3 - Olaparib + Letrozole (Treatment Period 3) |
|---|---|---|
| Effect of Letrozole on Exposure to Olaparib - Cmax ss | 10.05 ± 30.2 | 10.48 ± 33.6 |
Tamoxifen, N-DMT and endoxifen AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios
| microgram x hour/millilitre (mcg*h/mL) | Cohort 1 - Tamoxifen Alone (Treatment Period 2) | Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) |
|---|---|---|
| PK analysis of tamoxifen | 2233 ± 31.9 | 2751 ± 28.9 |
| PK analysis of N-DMT | 3189 ± 28.8 | 2955 ± 37.3 |
| PK analysis of endoxifen | 119.3 ± 66.1 | 115.8 ± 64.8 |
Olaparib AUC0-τ, in the presence and absence of co-administered tamoxifen, and associated AUC0-τ treatment ratios
| mcg*h/mL | Cohort 1 - Olaparib (Treatment Period 1) | Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) |
|---|---|---|
| Effect of Tamoxifen on Exposure to Olaparib - AUC0-τ | 62.12 ± 51.6 | 42.27 ± 60.6 |
Anastrozole Area under plasma concentration-time curve over the dosing interval at steady state (AUC0-τ), in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios
| mcg*h/mL | Cohort 2 - Anastrozole Alone (Treatment Period 2) | Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) |
|---|---|---|
| Effect of Olaparib on Exposure to Anastrozole - AUC0-τ | 696.8 ± 36.6 | 582.5 ± 31.6 |
Olaparib AUC0-τ, in the presence and absence of co-administered anastrozole, and associated AUC0-τ treatment ratios
| mcg*h/mL | Cohort 2 - Olaparib (Treatment Period 1) | Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) |
|---|---|---|
| Effect of Anastrozole on Exposure to Olaparib - AUC0-τ | 55.49 ± 53.8 | 44.33 ± 63.6 |
Letrozole AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios
| mcg*h/mL | Cohort 3 - Letrozole Alone (Treatment Period 2) | Cohort 3 - Olaparib + Letrozole (Treatment Period 3) |
|---|---|---|
| Effect of Olaparib on Exposure to Letrozole - AUC0-τ | 2292 ± 36.7 | 2167 ± 38.0 |
Olaparib AUC0-τ, in the presence and absence of co-administered letrozole, and associated AUC0-τ treatment ratios
| mcg*h/mL | Cohort 3 - Olaparib (Treatment Period 1) | Cohort 3 - Olaparib + Letrozole (Treatment Period 3) |
|---|---|---|
| Effect of Letrozole on Exposure to Olaparib - AUC0-τ | 61.77 ± 43.2 | 67.82 ± 44.1 |
Collected over For Part A, adverse events (AEs) were collected from the date of first dose up to last dose of study medication in Part A for patients continuing to Part B, or up to 30 days after last dose for patients who did not enter Part B (up to approximately 2 months). For Part B, AEs were collected from date of first dose in Part B up to 30 days after last dose (up to approximately 18 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - Tamoxifen | 1/30 (3.3%) | 2/30 (6.7%) | 27/30 (90%) |
| Cohort 2 - Anastrozole | 1/23 (4.3%) | 0/23 (0%) | 20/23 (87%) |
| Cohort 3 - Letrozole | 1/26 (3.8%) | 0/26 (0%) | 20/26 (76.9%) |
| Olaparib (Part B) | 1/69 (1.4%) | 22/69 (31.9%) | 66/69 (95.7%) |
| Event | Cohort 1 - Tamoxifen | Cohort 2 - Anastrozole | Cohort 3 - Letrozole | Olaparib (Part B) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/30 | 0/23 | 0/26 | 5/69 |
| AscitesGastrointestinal disorders | 1/30 | 0/23 | 0/26 | 0/69 |
| VomitingGastrointestinal disorders | 1/30 | 0/23 | 0/26 | 1/69 |
| Device OcclusionGeneral disorders | 0/30 | 0/23 | 0/26 | 2/69 |
| Urinary Tract InfectionInfections and infestations | 0/30 | 0/23 | 0/26 | 2/69 |
| UrosepsisInfections and infestations | 0/30 | 0/23 | 0/26 | 2/69 |
| ConstipationGastrointestinal disorders | 0/30 | 0/23 | 0/26 | 2/69 |
| Anaemia MacrocyticBlood and lymphatic system disorders | 0/30 | 0/23 | 0/26 | 1/69 |
| TachycardiaCardiac disorders | 0/30 | 0/23 | 0/26 | 1/69 |
| DiplopiaEye disorders | 0/30 | 0/23 | 0/26 | 1/69 |
| Event | Cohort 1 - Tamoxifen | Cohort 2 - Anastrozole | Cohort 3 - Letrozole | Olaparib (Part B) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 16/30 | 7/23 | 11/26 | 28/69 |
| FatigueGeneral disorders | 12/30 | 6/23 | 9/26 | 30/69 |
| VomitingGastrointestinal disorders | 6/30 | 4/23 | 4/26 | 22/69 |
| AnaemiaBlood and lymphatic system disorders | 6/30 | 3/23 | 3/26 | 18/69 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/30 | 2/23 | 1/26 | 18/69 |
| Decreased AppetiteMetabolism and nutrition disorders | 2/30 | 4/23 | 3/26 | 13/69 |
| DiarrhoeaGastrointestinal disorders | 5/30 | 1/23 | 3/26 | 12/69 |
| HeadacheNervous system disorders | 3/30 | 1/23 | 4/26 | 12/69 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/30 | 2/23 | 1/26 | 12/69 |
| RashSkin and subcutaneous tissue disorders | 0/30 | 4/23 | 2/26 | 3/69 |
All patients enrolled in Part A of the study and who received at least 1 dose of olaparib were included in the baseline analysis.
| Age, Continuous(years) | Cohort 1 - Tamoxifen | Cohort 2 - Anastrozole | Cohort 3 - Letrozole | Total |
|---|---|---|---|---|
| Mean | 52.6 ± 11.32 | 59.4 ± 11.68 | 64.0 ± 7.79 | 58.3 ± 11.37 |
| Sex: Female, Male(Participants) | Cohort 1 - Tamoxifen | Cohort 2 - Anastrozole | Cohort 3 - Letrozole | Total |
|---|---|---|---|---|
| Female | 26 | 18 | 20 | 64 |
| Male | 4 | 5 | 6 | 15 |
| Sex: Female, Male(Participants) | Cohort 1 - Tamoxifen | Cohort 2 - Anastrozole | Cohort 3 - Letrozole | Total |
|---|---|---|---|---|
| Female | 26 | 18 | 20 | 64 |
| Male | 4 | 5 | 6 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 - Tamoxifen | Cohort 2 - Anastrozole | Cohort 3 - Letrozole | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 30 | 23 | 26 | 79 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 - Tamoxifen | Cohort 2 - Anastrozole | Cohort 3 - Letrozole | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 2 |
| White | 27 | 22 | 24 | 73 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
Ran from Sep 2014 to primary completion in Apr 2015, 7 months.
Results were first posted in Jun 2016, 1 year 1 month after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 7 months is below that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Olaparib · Tamoxifen · Anastrozole · Letrozole